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Rheumatoid arthritis (RA) is a systemic autoimmune disease whose main extra‑articular organ 
affected is the lung, sometimes in the form of diffuse interstitial lung disease (ILD) and conditions the 
prognosis. A multicenter, observational, descriptive and cross‑sectional study of consecutive patients 
diagnosed with RA‑ILD. Demographic, analytical, respiratory functional and evolution characteristics 
were analyzed to evaluate the predictors of progression and mortality. 106 patients were included. 
The multivariate analysis showed that the diagnostic delay was an independent predictor of mortality 
(HR 1.11, CI 1.01–1.23, p = 0.035). Also, age (HR 1.33, 95% CI 1.09–1.62, p = 0.0045), DLCO (%) (HR 
0.85, 95% CI 0.73–0.98, p = 0.0246), and final SatO2 (%) in the 6MWT (HR 0.62, 95% CI 0.39–0.99, 
p = 0.0465) were independent predictor variables of mortality, as well as GAP index (HR 4.65, 95% 
CI 1.59–13.54, p = 0.0051) and CPI index (HR 1.12, 95% CI 1.03–1.22, p = 0.0092). The withdrawal of 
MTX or LFN after ILD diagnosis was associated with disease progression in the COX analysis (HR 2.18, 
95% CI 1.14–4.18, p = 0.019). This is the first study that highlights the diagnostic delay in RA‑ILD is 
associated with an increased mortality just like happens in IPF.
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RA  Rheumatoid arthritis
RA-ILD  Rheumatoid arthritis associated interstitial lung disease
RPC  Reactive protein C
SatO2  Oxygen saturation
SD  Standard deviation
SEPAR  Respiratory Spanish Society
UIP  Usual interstitial pneumonia
Rheumatoid arthritis (RA) is characterized by inflammation of synovial tissues and joint destruction that may 
involve other organs, including the  lung1. Interstitial lung disease (ILD) is a common manifestation of RA and 
may precede the joint  inflammation2. ILD associated to RA (RA-ILD) presents clinical and radiological features 
similar to idiopathic  ILDs3. The prevalence of RA-ILD varies depending on the method used to diagnose the 
disease and the population under  study4. Several studies based on reference cohorts have estimated a prevalence 
ranging between 1 and 58%5,6. According to Bongartz et al. approximately 1 in 10 patients with RA will be diag-
nosed of ILD during the course of their  disease6.
ILD is one of the main causes of mortality in  RA4. Predicting the evolution and outcome of RA-ILD patients is 
difficult because the evidence is based on small population and short-term follow-up studies. The most frequent 
radiological and histological pattern in RA-ILD is usual interstitial pneumonia (UIP)7. Furthermore, this pat-
tern is associated with higher mortality compared to others such as non-specific interstitial pneumonia (NSIP). 
In fact, the survival of RA-ILD patients with a UIP pattern is closer to that patients diagnosed of idiopathic 
pulmonary fibrosis (IPF)8.
Oher factors associated with a higher mortality in RA-ILD are age, male sex, worse pulmonary function at 
diagnosis, duration of RA, disease RA activity, extensive lung involvement on chest HRCT and elevated serum 
levels of Krebs von den Lungen 6 (KL-6)  biomarker9–13. Although these findings are all based on small series of 
cases, they have been reproduced consistently in different patient cohorts. Furthermore, predictive factors of 
disease progression are the presence of UIP pattern, high titers of anti-citrullinated cyclic peptide (ACPA) anti-
bodies, baseline deterioration of DLCO, a %FVC decline ≥ 10% during the follow-up, and elevated serum levels of 
interleukin 6 (IL-6) and KL-6. However, there is no clear definition of progression specifically for RA-ILD6,14–17.
Other reasons that make difficult to predict survival of RA-ILD patients is the heterogeneity in their evolution 
and the absence of an individual variable that is sufficiently accurate to predict mortality. In this regard, the use of 
multidimensional risk scales can be useful for physicians. The main ones are the GAP index that combines age, 
sex and pulmonary physiologic values and the composite physiologic index (CPI) that only includes pulmonary 
physiologic  characteristics18,19. These models were originally developed for IPF but recent studies have assessed 
the utility of these predictive models in RA-ILD20. A better predictive prognostic model could help in setting 
the appropriate timing for lung transplantation or optimizing treatments.
Finally, the potential harmful effect of some common medications for RA remains controversial. There is 
not enough evidence to recommend a specific treatment for RA-ILD, consequently the optimal treatment for 
RA-ILD has not yet been  established21. Current treatment regimens usually include corticosteroid therapy, 
methotrexate -MTX- , leflunomide -LEF-, and biologic disease-modifying anti-rheumatic drugs (e.g. rituximab, 
abatacept), immunosuppressant agents (cyclophosphamide and Mycophenolate Mofetil), and antifibrotic treat-
ment (nintedanib)22. In counterpoint frequently used treatments, as MTX and LEF, have also been implicated 
in the development of pneumonitis or exacerbation of an existing  ILD23, although the use of MTX has been 
recently associated with a better  outcome24,25. In addition, some studies have shown an increased risk of infec-
tions associated to the immunosuppressive  treatments26.
The aims of this study are: (a) to evaluate the predictive factors of mortality, (b) to investigate the potential 
associated factors to ILD progression.
Methods
Patient population. This is a multicenter, observational, descriptive and cross-sectional study of consecu-
tive patients with diagnosis of RA-ILD from nine Spanish hospitals. Clinical records were reviewed between 
2013 and 2018. The diagnosis of RA was done fulfilling ACR/EULAR 2010  criteria27 and the CTD-ILD classifica-
tion according to the 2003 Respiratory Spanish Society (SEPAR)  consensus3. The ILD pattern was identified and 
defined by HRCT. Patients with diagnosis of different CTD or other respiratory diseases were excluded. Only 
patients with ≥ 3 pulmonary function test measurements during the follow-up were included.
The Regional Research Ethics Committee of Galicia approved the study protocol (Registration Code 
2016/176). Each participating hospital obtained the ethic approval from the local Human Research Ethics Com-
mittee. Informed consent was obtained from each patient.
Procedures were in accordance with guidelines established in the Declaration of Helsinki, and with the prin-
ciples of Good Clinical Practices (GCPs).
Collected data and definitions. Demographic, epidemiological, radiological and treatment data were 
collected. Pulmonary disease progression was considered if the patient presented any of the following criteria: 
forced vital capacity (FVC) decrease ≥ 10%, diffusion capacity for carbon monoxide (DLCO) decrease ≥ 15%, 
radiological increase of lung fibrotic signs or death. Respiratory infectious events were defined as episodes of 
respiratory deterioration with or without respiratory failure that requires antibiotic treatment and may have 
required hospitalization. Heart failure or other non-respiratory reasons of hospitalization were excluded.
Two independent ILD expert radiologists evaluated the HRCT images over time and considered worsening 
of fibrotic radiological signs when an increase of more than 5% was identified.
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Time to diagnosis of ILD from the onset of symptoms was classified as follows;  < 12 months, 12–24 months, 
> 24 months (the last two groups were considered diagnostic delay).
The GAP index was calculated using the continuous predictor variables sex, age, and the pulmonary 
functional values, through the online model (www. acpon line. org/ journ als/ annals/ extras/ gap)18. Compos-
ite physiologic index (CPI) was calculated using the formula: CPI = 91-(0.65xDLCO% pred.)–(0.53xFVC% 
pred.) + (0.34 × FEV1% pred.)19.
Statistical analysis. The distribution of the continuous variables was verified with the Shapiro–Wilk test. 
The Student T-test was used to compare continuous variables if there was a normal distribution. If it did not 
have a normal distribution the Mann–Whitney U-test was used. The chi-squared test or Fisher test was used for 
comparison of categorical variables. Logistic regression analysis was used to identify significant variables capable 
of predicting respiratory infectious events.
Survival and progression differences between groups were evaluated by Kaplan–Meier analysis. Survival 
curves were compared with the log-rank test. A univariate Cox regression was performed to calculate the haz-
ard ratio (HR) with a 95% confidence interval (CI) of the independent variables. A multivariate Cox regression 
model was carried out adjusting for all confounding variables that in univariate analysis had a p value < 0.2. Time 
to death was obtained from medical records and the censoring time was defined as the last medical visit or the 
end of the study at December 31, 2018.
It was considered appropriate to determine a cut-off level of CRP, ESR and RF by maximizing the Youden 
index from ROC curves for analysis of progression instead of using continuous data because they did not satisfy 
the assumption that the log hazard increased linearly with the  covariate28. Since including variables with substan-
tial missing data can introduce significant bias, anti-CCP antibodies and DAS28 score, which had a substantial 
number of missing values, were not included in the models of survival and progression.
The results were reported as mean ± standard deviation (SD). P < 0.05 was considered statistically significant. 
MedCalc Statistical Software version 14.8.1 (MedCalc Software bvba, Ostend, Belgium) was used to perform 
all the analysis.
Results
Population. A total of 106 patients with RA-ILD were included, 61 women (57.5%). The mean age was 
70.21 ± 9.8 years. RA was diagnosed 126.66 ± 117.28 months before the diagnosis of ILD. In 10 patients (9.43%) 
the ILD was present at the onset of disease. 40.6% of patients (n = 43) were never smokers. A confident UIP 
pattern in the HRCT was present in 51.9% of the patients. At the moment of ILD diagnosis 10 patients (9.43%) 
presented severe oxygen desaturation on effort (defined as SatO2 < 88% in the 6MWT). Therefore, a delay in the 
ILD identification was observed in a high proportion of patients. An abnormally high levels of anti-CCP was 
observed in 63 cases (66.8%). The rest of the characteristics are described in Table 1.
Predictors of disease progression. After defining the pre-specified variables of ILD progression, 53 
patients (50%) presented disease progression. Of those progressors, 35 patients presented a FVC decline > 10%, 
25 presented a decrease > 15% of DLCO and 24 an increase of the lung fibrotic signs in the HRCT. The respira-
tory functional impairment (FVC% and DLco%) is represented differentiating between the groups of progres-
sive and non-progressive patients in the Fig. 1a, b.
After multivariate COX analysis, withdrawal of MTX or LFN after ILD diagnosis was associated to ILD pro-
gression in the first 5 years (HR 2.18, 95% CI 1.14–4.18, p = 0.019) (Table 2). From 88 patients that were treated 
with MTX or LFN previous ILD diagnosis , the medication was changed in 27 cases after the ILD identification 
due to the potential drug-induced ILD effect of MTX (n = 22) or the existence of extensive pulmonary fibrosis 
(n = 5). Patients in whom MTX and/or LFN were suspended had initially similar radiological pattern (p = 0.874) 
and respiratory function test values, FVC and DLCO, compared to those who were not discontinued (Supple-
mentary data, Table S1). Disease progression free-survival curves over time are displayed in Fig. 2.
Survival predictors. Of the 106 subjects reviewed, 18 subjects died (17%). All of them presented fibrotic 
ILD. Causes of death were mostly related to ILD: 10 patients died of ILD progression, 3 of acute pneumonia 
and 4 of acute exacerbation of ILD. A missing data about the cause of death was present in one patient and no 
patient of the cohort underwent lung transplantation. Respiratory functional impairment in deceased patients 
is represented in Fig. 3a, b.
Patients had a median survival of 41.16 ± 27.94 months. Age (HR 1.33, 95% CI 1.09–1.62, p = 0.0045), DLCO 
predicted (%) (HR 0.85, 95% CI 0.73–0.98, p = 0.0246) and final oxygen saturation in the 6MWT (HR 0.62, 95% 
CI 0.39–0.99, p = 0.0465) were independent predictors of mortality in a multivariate model that included all those 
variables determined in the univariate analysis as a potentially influential predictors (Table 3).
The median time to ILD diagnosis after appearance of respiratory symptoms in RA patients was 
14.36 ± 15.3 months. This information was available for 101 subjects. Also, diagnostic delay was an independ-
ent predictor of survival (HR 1.11, CI 1.01–1.23, p = 0.035) in the multivariate analysis, with no significant 
differences depending on received treatments or initial pulmonary functional severity (Supplementary data, 
Tables S2 and S3). The representation of survival by Kaplan–Meier curves, dividing the diagnostic delay in less 
than 12 months, 12–24 months and more than 24 months from the beginning of the respiratory symptomatol-
ogy is displayed in Fig. 4.
Both, CPI and GAP indexes were predictors of mortality in the univariate Cox analysis. After adjusting for 
radiological pattern on HRCT, RPC > 23 mg/L, ESR > 33 mm/H, ILD diagnostic delay and final oxygen satura-
tion in the 6MWT, GAP index remained as a significant predictor of mortality (HR 4.65, 95% CI 1.59–13.54, 
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p = 0.0051). Furthermore, CPI index was a significant predictor of mortality in the multivariate analysis adjusted 
by age, radiological pattern on HRCT, ESR > 33 mm/H, RPC > 23 mg/L, ILD diagnostic delay and final oxygen 
saturation in the 6MWT (HR 1.12, 95% CI 1.03–1.22, p = 0.0092) (Table 3).
Among the deceased subjects, the median survival was 76.66 ± 46.23 months (n = 3) in the GAP stage I, 
38.03 ± 17.35 months (n = 12) in the stage II and only 18 ± 9,54 months (n = 3) in the stage III. The best cut-
off point of CPI index for predicting mortality was 50.58. The median survival was 51 ± 34.31 months (n = 9) 
for patients with CPI < 50 points. Nevertheless if the CPI score was > 50 points, the median survival was 
31.33 ± 16.26 months (n = 9) (Fig. 5A, B) . The predictive value of CPI and GAP stages was assessed by ROC 
curve analysis (Fig. 6A, B).
Risk of respiratory infection in ILD‑RA treatments. Of the 106 RA-ILD subjects, 21 (19.8%) suffered 
respiratory infectious events. Ten patients (9.4%) were being treated with corticosteroids plus azathioprine and 
Table 1.  Characteristics of the entire RA-ILD cohort. RA: rheumatoid arthritis; ILD: interstitial lung disease; 
HRCT: high-resolution computed tomography; UIP: usual interstitial pneumonia; NSIP: non-specific 
interstitial pneumonia; OP: organizing pneumonia; ESR: erythrocyte sedimentation rate ; CRP: C-reactive 
protein; RF: rheumatoid factor; DAS: disease activity score, Anti CCP: anti-cyclic citrullinated peptide, FEV1: 
forced expiratory volume in one second, FVC: forced vital capacity; DLCO: diffusion capacity for carbon 
monoxide; 6MWT: six minutes walking test.
n = 106 % SD Min–Max
Gender (male/female) 45/61 42.5/57.5





Packs-year 48.58 49.91 10–285
RA evolution (months) 126.66 117.28 0–480
ILD evolution (months) 42.21 40.1 2–240




mMRC 0 30 28.3
mMRC 1 49 46.2
mMRC 2 20 18.9





ESR (mm/H) 39.39 42.54 3–367
CRP (mg/L) 25.52 58.9 0–507
RF (titer) 180.34 188.51 0–921
DAS28 score 3.80 1.47 1.68–6.7
Anti CCP (titer) 523.95 563.69 0.5–2776
SatO2 (%) 95.62 3.25 80–100
PaO2 (mmHg) 73.26 12.91 47–107
FEV1FVC (%) 76.64 9.92 32–115
FEV1 predicted (%) 85.49 21.71 41–143
FVC predicted (%) 87 22.2 45,4–188
DLCO predicted (%) 65.1 18.51 26.2–108
6MWT distance (meters) 404.69 88.19 199–620
Initial SatO2 6MWT (%) 95.62 2.42 88–99
Final SatO2 6MWT (%) 91.93 3.67 78–98
Acute exacerbations 9 8.5
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18 (17%) with biological agents. Logistic regression model, as reflected in Table 4, showed that the association 
of azathioprine plus corticosteroids was related with an increased risk of respiratory infection (OR 20.86, 95% 
CI 3.5–124.28, p = 0.0008).
Discussion
This is the first study that has identified diagnostic delay as a variable associated with an increased mortality in 
RA-ILD patients, independently of received treatment. The suspension of MTX and/or LFN was more frequently 
present among those cases that presented ILD progression. RA-ILD is the most frequent extra-articular mani-
festation in RA and it’s considered the second cause of mortality after cardiovascular comorbidities in  RA4,6.
The patient characteristics of this cohort are consistent with the previous published  data29,30, highlighting 
the high prevalence of patients with tobacco exposure as well as the predominant UIP radiological pattern at 
diagnosis. Furthermore, in line with previous  work6,31, age and pulmonary function were identified as predictive 
mortality variables.
Interestingly, this study demonstrates that the ILD diagnostic delay is a predictive factor of mortality in RA-
ILD. After multivariate analysis, disease severity, radiologic pattern, sex and age did not influence in this result. 
IPF studies had suggested that the diagnostic delay increases mortality, due in part to the late evaluation by a mul-
tidisciplinary committee and the potential access to specialized and comprehensive treatment  management32–34.
Regarding other predictors of mortality, age, DLCO at diagnosis and significant desaturation to effort in 
6MWT were independent predictive variables in this cohort. In our study, survival was 41 months on average, 
similar to  IPF8,9,17,35. There are several studies that have evaluated predictors of mortality in RA-ILD, including 
Figure 1.  Respiratory functional impairment of the global recruited cases differentiating between groups of 
progressive and non-progressive patients. FVC (%) impairment is represented in the graph (a) and DLCO (%) 
impairment is represented in the graph (b).
Table 2.  Cox analysis of progression predictors. mMRC: modified Medical Research Council; ESR: 
erythrocyte sedimentation rate ; CRP: C-reactive protein; RF: rheumatoid factor; FVC: forced vital capacity; 
DLCO: diffusion capacity for carbon monoxide; UIP: usual interstitial pneumonia; HRCT: high-resolution 
computed tomography; MTX: methotrexate; LFN: leflunomide.
Variable
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Age 1.02 (0.98–1.06) 0.2345
Male, sex 1.31 (0.71–2.41) 0.3884
Ever smoker 0.97 (0.52–1.81) 0.9331
Dyspnea 2–3 mMRC 0.81 (0.4–1.66) 0.5826
Crackles 2.06 (1.01–4.2) 0.0487 1.76 (0.91–3.41) 0.0925
CRP > 3 (mg/L) 0.74 (0.36–1.50) 0.4109
ESR > 77 (mm/H) 0.74 (0.26–2.12) 0.5831
RF titer > 70 0.64 (0.29–1.4) 0.2672
FVC predicted (%) 0.99 (0.97–1.002) 0.1038 0.99 (0.97–1.01) 0,1574
DLCO predicted (%) 0.99 (0.97–1.008) 0.2741
UIP pattern on HRCT 1.79 (0.96–3.34) 0.0637 1.72 (0.92–3.2) 0.0899
MTX or LFN discontinuation after ILD diagnosis 2.08 (1.12 -3.85) 0.021 2.18 (1.14–4.18) 0.0190
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the  age8,9,17,35,36. The main limitations of these studies have always been the methodology and sample size. Other 
variables as the disease severity assessed by DLCO have also been confirmed by Zamora et al.11. We also suggest 
desaturation during effort as a prognostic marker in RA-ILD, which is already known as poor prognostic factor 
in IPF but it had not yet been suggested in RA-ILD  population37.
No significant differences in mortality were found according to the HRCT pattern of presentation, although 
all of them showed lung fibrotic features. Previous studies have suggested a different survival in RA-ILD with 
UIP pattern vs NSIP  pattern38. However, this has not been a universal  finding15, with a recent study by Zamora-
Legoff et al. proving no association between different patterns and  mortality16. The discrepancies in the previous 
reported cohorts could be due to the heterogeneity of NSIP and the broad spectrum of progression depending 
on the presence of fibrotic changes. Similar to IPF, the clue would be the presence of fibrotic radiological findings 
that are associated with disease progression; honeycombing or traction  bronchiectasis39. Therefore, a RA-ILD 
patient with a UIP or a fibrotic NSIP pattern would have higher probability to death or disease progression than 
non-fibrotic NSIP or other forms of RA-ILDs.
The existence of this large number of prognostic variables of survival suggests the possibility of using mul-
tidimensional models in RA-ILD. Several multidimensional risk scales have been created and validated in ILD 
including gender, age and lung function (GAP index) for  IPF18 and subsequently ILD-GAP index for non-IPF 
 ILD40. In the Zamora-Legoff study, the GAP model demonstrated good discriminative and predictive value 
for RA-ILD in contrast to the ILD-GAP model which did not perform  well16. This partially coincides with our 
Figure 2.  Kaplan–Meier curve for disease progression in RA-ILD during five years period, grouped by 
discontinuing or not MTX and/or LFN at the moment of ILD diagnosis (Log Rank Test: p = 0.0139).
Figure 3.  Respiratory functional impairment in deceased patients. FVC (%) impairment is represented in the 
graph (a) and DLCO (%) impairment is represented in the graph (b).
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results where the GAP index is a good marker of mortality in the multivariate analysis when adjusted for all 
those variables that can be predictive and are not included in the index itself. As we have shown, Numri et al. 
demonstrated in a multivariate analysis adjusted for age that the CPI index was also a predictor of mortality 
together with  DLCO20.
MTX and LFN are first-line drugs in the treatment of RA to which other drugs are added during the course 
of the  disease41. The association between MTX and acute pulmonary toxicity is well known. Sathi et al. estimated 
Table 3.  Univariate and multivariate analysis of mortality predictors. mMRC: modified Medical Research 
Council; UIP: usual interstitial pneumonia; HRCT: high-resolution computed tomography; CRP: C-reactive 
protein; ESR: erythrocyte sedimentation rate ; RF: rheumatoid factor; FVC: forced vital capacity; DLCO: 
diffusion capacity for carbon monoxide; 6MWT: six minutes walking test; GAP: gender [G], age [A], and 
lung physiology variables [P] index; CPI: composite physiologic index. a Adjusted by ESR > 33 mm/H, 
CRP > 23 mg/L, radiological pattern on HRCT, respiratory symptoms duration until ILD diagnosis, and final 
oxygen saturation in the 6MWT. b Adjusted by ESR > 33 mm/H, CRP > 23 mg/L, radiological pattern on HRCT, 
respiratory symptoms duration until ILD diagnosis, final oxygen saturation in the 6MWT and age.
Variable
Univariate Multivariate
HR (95% CI) p HR (95% CI) p
Male, sex 1.98 (0.77–5.09) 0.1597 0.41 (0.03–4.54) 0.4713
Age 1.10 (1.04–1.17) 0.0013 1.33 (1.09–1.62) 0.0045
Ever-smoker 0.89 (0.35–2.28) 0.8106
Respiratory symptoms duration until ILD diagnosis 1.03 (1.02–1.05) 0.0001 1.11 (1.01–1.23) 0.035
Dyspnea 2–3 mMRC 1.78 (0.62–5.15) 0.2861
Crackles 1.02 (0.40–2.59) 0.9612
UIP pattern on HRCT 2.19 (0.78–6.18) 0.1371 0.45 (0.03–5.89) 0.5450
CRP > 23 (mg/L) 3.61 (1.30–9.98) 0.0136 0.23 (0.01–3.12) 0.2731
ESR > 33 (mm/H) 1.89 (0.66–5.41) 0.2397
RF titer > 165 0.38 (0.08–1.77) 0.2228
FVC % pred 0.95 (0.93–0.98) 0.0015 0.99 (0.87–1.13) 0.96
DLCO % pred 0.94 (0.91–0.97) 0.0008 0.85 (0.73–0.98) 0.0246
6MWT distance (meters) 0.99 (0.98–0.99) 0.0026 1.01 (0.98–1.02) 0.8733
6MWT final SatO2 0.83 (0.75–0.92) 0.0002 0.62 (0.39–0.99) 0.0465
GAP  indexa 3.25 (2.04–5.17)  < 0.0001 4.65 (1.59–13.54) 0.0051
CPI  indexb 1.09 (1.04–1.14) 0.0001 1.12 (1.03 -1.22) 0.0092
Figure 4.  Kaplan–Meier survival curves for patients with RA-ILD. Overall survival according for diagnostic 
delay (Log Rank Test: p = 0.0051).
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Figures 5.  Kaplan–Meier survival curves for patients with RA-ILD. Survival according for GAP stage (A) (Log 
Rank Test: p < 0.001) and for CPI with cut-off point of 50 (B) (Log Rank Test: p < 0.0001).
Figure 6.  (A) ROC curve for CPI and GAP indexes. For CPI, the AUC was 0.742 and the best cut-off point for 
predicting survival was 50.58 (sensitivity of 50% and specificity of 96.2%). The AUC for GAP ROC curve was 
0.857 with a best cut-off point of 3 (sensitivity 83.3% and specificity 85.2%). (B) Receiver operator characteristic 
(ROC) curves for GAP stage (I, II and III) and CPI (with a cut-off point of 50) to predict mortality in AR-ILD 
patients.
Table 4.  Logistic regression model for respiratory infection risk.
Variable
Univariate Multivariate
OR (95% CI) p OR (95% CI) p
Corticosteroids plus azathioprine 13.66 (3.15–59.23) 0.0005 20.86 (3.50–124.28) 0.0008
Flu vaccination 1.22 (0.37–4.07) 0.7424 4.28 (0.67–27.29) 0.1241
Pneumococcal vaccination 1.21 (0.46–3.15) 0.6964 0.84 (0.27–2.56) 0.756
Antibiotic prophylaxis 4.37 (0.5781–33.00) 0.153 5.20 (0.50–53.49) 0.1655
Biological treatment 1.73 (0.54–5.55) 0.3561 1.57 (0.38–6.42) 0.53
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the incidence of MTX-induced pneumonitis at 1 per 192 patient-years and usually occurs during the first year 
of  treatment42. Since MTX can exacerbate a preexisting lung disease the American College of Rheumatology 
recommends not using it in patients with symptomatic RA-ILD43. However, the association between MTX and 
appearance of a chronic ILD other than a hypersensitivity reaction is not so clear. Recent studies do not sup-
port this  association44. On the other hand, LFN has been less frequently associated with ILD exacerbation or 
development of new  ILD45. In our cohort, discontinuation of MTX or LFN after the diagnosis of fibrotic ILD in 
RA patients was associated with disease  progression46. Our observation, together with recent data, suggests that 
withdrawing MTX in fibrotic ILD patients doesn’t avoid disease progression and also it points the fact that pro-
spective clinical trials are required for evaluating the exact role of MTX in fibrotic RA-ILD43. Thus, we consider 
that it may be necessary to monitor lung function and perform an HRCT before starting MTX or other drugs 
that may present pulmonary toxicity.
Regardless of the role of MTX and LFN in RA-ILD disease, we have to consider adding a treatment focused 
on lung involvement, such as biological agents (e.g. rituximab, abatacept) or antifibrotic treatment such as nin-
tedanib after the recent clinical trials in progressive pulmonary fibrosis. We must individualize the treatment, 
differentiating the radiological pattern, the severity and progression of lung involvement to better target the 
proper treatment from a multidisciplinary  approach39–41.
Respiratory infection or community-acquired pneumonia are the most common type of infections seen in 
patients with  RA47. A retrospective study defined serious infection as the requirement of antimicrobial therapy 
and hospitalization. The authors observed that the highest infection rate was in those patients with a daily 
prednisone use > 10 mg per  day48. The use of corticosteroids concurrently with another immunosuppressant 
such as azathioprine increased mortality, hospitalization rate and serious adverse events in IPF mainly due to 
pulmonary infection and the presence of telomere  shortening49. Similar results were obtained in the PANTHER 
study where increased risks of death and hospitalization were observed in patients with IPF who were treated 
with a combination of prednisone, azathioprine, and acetylcysteine, as compared with  placebo50. In our study 
it seems that the use of prednisone at a dose greater than 10 mg together with azathioprine is associated with a 
higher occurrence of respiratory infections in a multivariate logistic model corrected by pneumococcal vaccina-
tion, flu vaccination and antibiotic prophylaxis. No data on telomere length was available since it is not a current 
standardized evaluation in these patients.
Our study has several limitations. The major one is related to the retrospective analysis design despite being 
consecutive cases collected in a multicenter study.
Incomplete clinical information or loss of variables are a constant in this type of studies, hence the need to 
eliminate some variables such as DAS28 or anti-CCP antibodies to avoid biasing the results in the survival and 
progression models. Due to the retrospective design of the study and the limited number of patients for analyz-
ing by subgroups (depending on all received therapies), analyzing the impact of other treatments on progres-
sion and mortality was not feasible. The majority of patients were assessed in the pulmonology department due 
to respiratory symptoms. Thus, it is possible that asymptomatic patients and therefore milder cases were not 
included. Finally, the evaluation of radiological patterns in the HRCT was not centralized, although in all cases 
it was done in a specialized ILD consultation and after the evaluation in a multidisciplinary discussion with 
expert ILD radiologists.
In conclusion, the delay in identifying fibrotic ILD in RA patients increases the probability of death or disease 
progression. The existence of several prognostic variables in RA-ILD makes multidimensional predictive models 
also useful. Early referral to expert ILD consultation would improve the prognostic and treatment approach, 
including the proper referral to lung transplant.
Data availability
The dataset generated and analysed during the current study is available from the corresponding on reasonable 
request.
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